


Leupeptin

Cat. No.:	HY-18234
CAS No.:	55123-66-5
Molecular Formula:	C ₂₀ H ₃₈ N ₆ O ₄
Molecular Weight:	426.55
Target:	Ser/Thr Protease; Virus Protease; Cathepsin
Pathway:	Metabolic Enzyme/Protease; Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Leupeptin is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin potently inhibits serine, cysteine and threonine proteases. Leupeptin inhibits M ^{Pro} (the main protease of SARS-CoV-2) and also has anti-inflammatory activity ^{[1][2][3]} .								
IC₅₀ & Target	Cathepsin B, Cathepsin H, Cathepsin L, Ser/Thr Protease, Mpro ^{[1][2][3]} .								
In Vitro	<p>Leupeptin (0.06-200 μM; 72 h) significantly decreases copy numbers of SARS-CoV-2 viral RNA (vRNA) in Vero cells^[1]. Leupeptin inhibits RNA levels of SARS-CoV-2 in Vero cells, with an EC₅₀ value of 42.34 μM^[1]. Leupeptin has some inhibitory activity against M^{Pro}, with an IC₅₀ value of 127.2 μM^[1]. Leupeptin againsts human coronavirus strain 229E with an IC₅₀ value of 0.4 μg/mL (about 1 μM)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>RT-PCR^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Vero cells</td> </tr> <tr> <td>Concentration:</td> <td>0.06-200 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Significantly decreased copy numbers of SARS-CoV-2 viral RNA (vRNA).</td> </tr> </table>	Cell Line:	Vero cells	Concentration:	0.06-200 μM	Incubation Time:	72 h	Result:	Significantly decreased copy numbers of SARS-CoV-2 viral RNA (vRNA).
Cell Line:	Vero cells								
Concentration:	0.06-200 μM								
Incubation Time:	72 h								
Result:	Significantly decreased copy numbers of SARS-CoV-2 viral RNA (vRNA).								
In Vivo	<p>Leupeptin (0, 9, 18, 36 mg/kg; i.p.; single) is well tolerated by the animals and produces a strong, dose-dependent increase in LC3b-II in both the total tissue extracts and the lysosome and autophagosome-enriched pellet fraction^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C57BL/6NCrI male mice (6-8 weeks old, 20-25 g)^[1].</td> </tr> <tr> <td>Dosage:</td> <td>0, 9, 18, 36 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; single</td> </tr> <tr> <td>Result:</td> <td>Promoted the accumulation of LC3b-II in mouse liver.</td> </tr> </table>	Animal Model:	C57BL/6NCrI male mice (6-8 weeks old, 20-25 g) ^[1] .	Dosage:	0, 9, 18, 36 mg/kg	Administration:	Intraperitoneal injection; single	Result:	Promoted the accumulation of LC3b-II in mouse liver.
Animal Model:	C57BL/6NCrI male mice (6-8 weeks old, 20-25 g) ^[1] .								
Dosage:	0, 9, 18, 36 mg/kg								
Administration:	Intraperitoneal injection; single								
Result:	Promoted the accumulation of LC3b-II in mouse liver.								

CUSTOMER VALIDATION

- Nature. 2023 Jun;618(7966):799-807.
- Natl Sci Rev. 2021 Feb 10;8(7):nwab024.
- Neuro Oncol. 2022 Jun 21;noac157.
- J Clin Invest. 2022 Mar 1;132(5):e152170.
- Sci Adv. 2021 Jan 1;7(1):eabe1340.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Fu L, et al. Mechanism of Microbial Metabolite Leupeptin in the Treatment of COVID-19 by Traditional Chinese Medicine Herbs. *mBio*. 2021 Oct 26;12(5):e0222021.
- [2]. Haspel J, et al. Characterization of macroautophagic flux in vivo using a leupeptin-based assay. *Autophagy*. 2011 Jun;7(6):629-42.
- [3]. Aoyagi T, et al. Biological activities of leupeptins. *J Antibiot (Tokyo)*. 1969 Nov;22(11):558-68.
- [4]. Aoyagi T, et al. Biological activities of leupeptins. *J Antibiot (Tokyo)*. 1969 Nov;22(11):558-68.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA